aranesp darbepoetin alfa (rch) 20 microgram/0.5ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: water for injections; polysorbate 80; sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 100 microgram/0.5ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 40 microgram/0.4ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 50 microgram/0.5ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 10 microgram/0.4ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; sodium chloride; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp darbepoetin alfa (rch) 30 microgram/0.3ml injection syringe within a pen injector
amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.
aranesp 10 mcg
amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age
aranesp 100 mcg
amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age
aranesp 150 mcg
amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 150 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.
aranesp 20 mcg
amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 20 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age